Ulrich Zoeller, vice president, project management, general medicine for PPD, told us collaborating with Frenova supports the company’s mission of delivering access to patients and sites, “while helping to bend the cost-time curve of drug development.”
Frenova describes itself as the world's only drug and medical device contract clinical development services provider dedicated exclusively to renal research.
The new relationship will provide the global contract research organization (CRO) with access to Frenova’s global nephrology experts, as well as access to F1RST Up™ (Frenova Rapid STart Up).
As Outsourcing-Pharma.com previously reported, F1RST Up is a program dedicated to accelerating study startup by eliminating common administrative and contracting issues.
Frenova’s network spans 260 research sites across the US – including 15 F1RST Up sites – with 450 principal investigators and access to more than 183,000 active ESRD patients and 390,000 active CKD patients.
(Feature image: iStock/HYWARDS)